AIN457 provided rapid and significant comfort of symptoms in up to 81 percent of sufferers with psoriasis Novartis has announced positive results from three Stage II trials showing that AIN457 produced an instant and significant improvement of symptoms in sufferers with moderate-to-severe plaque psoriasis. The results were shown at the annual European Academy of Dermatology and Venereology Congress, in Lisbon, Portugal. The news headlines service writes, ‘Africa makes up about 39 of the 59 most at-risk countries in Maplecroft’s Food RISK OF SECURITY Index and offers nine of the 11 countries in the ‘extreme risk’ category, the Bath, England-based company said in a statement today’ .In adjusted analyses fully, however, the risk was no significant longer. This result was primarily due to adjustment for a number of psychiatric diagnoses , which is consistent with the presence of confounding by indication in the unadjusted evaluation. We had access and then maternal psychiatric circumstances diagnosed in psychiatric hospitals and psychiatric products , with no given information on cases diagnosed in primary care settings. A period was released by us of SSRI make use of before pregnancy, which allowed us to evaluate whether maternal usage of SSRIs before however, not during being pregnant was associated with an increased risk of subsequent autism spectrum disorders in the offspring. The elevated risk associated with this pattern of use similarly shows that any risk connected with SSRI use during pregnancy may be related to the indications for its use rather than causal effect.